OBJECTIVES: This study deals with the impact of regulatory measures represented by the drug categorization on the prescription and at the use of nonsteroidal and antiinflammatory drugs (NSAID) and asses measures of the state health policy and their application in the Slovak Republic within year 2009. METHODS: Analysis was conducted with key data represented by the medicine name and code, name of registration decision owner, maximum price of producer and importer, final medicine price, maximum copayment, prescription and indication restriction, the number of medicine packages. As data sources were used The List of Drugs. Analysis of categorizations in ATC group of drugs M01- NSAID, comparison of single changes and its significance. RESULTS: In year 2009 were 9,087,217 medicine packages from the group of NSAID expended. From this amount of medicine packages were 2,477,352 packages expended during first quartal of 2009, which represents the highest consumption of all four terms. The lowest consumption was noticed in period of second term reaching expenditure of only 2,020,514 medicine packages. Outstanding changes appeared by indometacine where prescription decreased from 9782 medicine packages to zero. Lornoxicam has appeared in third term as new medicine in categorization and his consumption increased to 3091 medicine packages in the fourth term. In all four terms dominated the same drugs on first ten places of medicine consumption (ibuprofen, diclofenac, nimesulid, combinations of ibuprofen, meloxicam, ketoprofen, flurbiprofen, piroxicam, naproxen, aceclofenac). CONCLUSIONS: Current state of categorization and functioning of professional bodies represent initial assumption of health policy asserting. Patient registries are helping tool in assessing effectiveness of medicines and cost efficacy and should be legislated. There is a disadvantage of administrative burden. Patient co- payment has increasing tendency due to removing responsibility for own health on patients.